{"id":48048,"date":"2022-09-07T13:01:39","date_gmt":"2022-09-07T11:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/"},"modified":"2022-09-07T13:01:39","modified_gmt":"2022-09-07T11:01:39","slug":"glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/","title":{"rendered":"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th<\/sup> Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nAn archived recording of the presentation will be available for 90 days on the GlycoMimetics website at https:\/\/ir.glycomimetics.com\/investor-relations<\/a>.\n<\/p>\n

\nAbout GlycoMimetics, Inc.<\/b>\n<\/p>\n

\nGlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company\u2019s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and data from clinical trials, planned or potential clinical development, regulatory interactions and submissions, and the commercialization and potential benefits and impact of the Company\u2019s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company\u2019s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2022, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Argot Partners
\n
Leo Vartorella \/ Carrie McKim
\n
212-600-1902
\n
Glycomimetics@argotpartners.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET. An archived recording of the presentation will be available for 90 days on the GlycoMimetics website … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48048","6":"format-standard","7":"category-industry"},"yoast_head":"\nGlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET. An archived recording of the presentation will be available for 90 days on the GlycoMimetics website ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-07T11:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220907005136\/en\/1560445\/21\/Logo-Glyco_%28002%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference\",\"datePublished\":\"2022-09-07T11:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"wordCount\":367,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907005136\\\/en\\\/1560445\\\/21\\\/Logo-Glyco_%28002%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"name\":\"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907005136\\\/en\\\/1560445\\\/21\\\/Logo-Glyco_%28002%29.jpg\",\"datePublished\":\"2022-09-07T11:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907005136\\\/en\\\/1560445\\\/21\\\/Logo-Glyco_%28002%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220907005136\\\/en\\\/1560445\\\/21\\\/Logo-Glyco_%28002%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET. An archived recording of the presentation will be available for 90 days on the GlycoMimetics website ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-07T11:01:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220907005136\/en\/1560445\/21\/Logo-Glyco_%28002%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference","datePublished":"2022-09-07T11:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/"},"wordCount":367,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220907005136\/en\/1560445\/21\/Logo-Glyco_%28002%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/","url":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/","name":"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220907005136\/en\/1560445\/21\/Logo-Glyco_%28002%29.jpg","datePublished":"2022-09-07T11:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220907005136\/en\/1560445\/21\/Logo-Glyco_%28002%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220907005136\/en\/1560445\/21\/Logo-Glyco_%28002%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/glycomimetics-to-participate-in-upcoming-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48048"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48048\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}